Allos Therapeutics Inc.

Allos Therapeutics Reports Third Quarter 2009 Financial Results.(Financial report)
Blood Weekly; 11/19/2009; 2017 words; Allos Therapeutics, Inc. (Nasdaq: ALTH) reported results...Company's common stock (see also Allos Therapeutics, Inc.). "During the quarter, we achieved...president and chief executive officer of Allos Therapeutics. "Importantly, this...

New Shire Board Member.
Vaccine Weekly; 11/18/2009; 425 words; ...Beecham, Mr Stout worked for many years at Schering-Plough. Mr Stout holds directorships at Allos Therapeutics, Inc, Jabil Circuit, Inc. and Airgas Inc. Matt Emmens, Chairman of Shire commented; "We are delighted to welcome David Stout to...

Allos Therapeutics to Present New Data on Folotyn at the American Society of Hematology Meeting.
Health & Beauty Close-Up; 11/17/2009; 995 words; Allos Therapeutics, Inc. has announced that abstracts from studies of Folotyn (pralatrexate...919 Location: 260-262 Ernest N. Morial Convention Center Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development...

Allos Therapeutics to Present at Upcoming Conferences.(Conference news)
Health & Beauty Close-Up; 11/12/2009; 521 words; Allos Therapeutics, Inc., a biopharmaceutical company committed...commercialization of anti-cancer therapeutics, announced that management will present...section of the Company's website at allos.com. The webcast will be available...

News and FDA Updates for Akorn (NASDAQ:AKRX), Allos (NASDAQ:ALTH), ArQule (Nasdaq:ARQL).
M2 Presswire; 11/11/2009; 1073 words; ...Updates for Akorn (NASDAQ:AKRX), Allos (NASDAQ:ALTH), ArQule (Nasdaq...Com On 10/11/09, Akorn, Inc. (NASDAQ:AKRX) a specialty...September 30, 2009. On 10/11/09, Allos Therapeutics, Inc. (NASDAQ:ALTH), a biopharmaceutical...